I have been contemplating buying VICL over the last few months.
Found an article that states the reason for the delay is because the statistical advantage has NOT been met and therefore they are extending the study to try to show an overall survival rate advantage which is there secondary endpoint. However the main premise of the study was to show a statistically higher response rate to the Allovectin than in the control arm, which has clearly not been met, otherwise the trial would have been stopped by now. Even if they reach the secondary endpoint of overall higher survival it will be small and clinically meaningless.
The argument that the study lasting longer than expected is positive is incorrect.
How do they know the statistical advantage has NOT been met when the trial is Blinded? They do not know the results. If they have know the results for this long and have not released them they are looking at law suits.
You do realize that this is not an article right? It's a blog written in November by a guy who has only written one blog. Just click on his profile and see that this is the only thing he has written. Even AF has more merit than him
Jeff, I took your advice and followed the Provectus link, seeing the dated Ted Cohen Seeking Alpha article from the Provectus blog. It may be worth reading what else Mr. Cohen has said about Vical since last summer (he remains LONG on Vical). There's plenty of posts on this MB to chew on in deciding whether Vical and its Allovectin vaccine are a good bet. But don't trust what you read on the Yahoo MB. Look deeper at facts about who else has a stake in tiny Vical vs. tinier Provectus, for example (which has just 1.5 million of cash). I wonder what your POV is on Merial's Oncept drug, which helps dogs live much longer with melanoma. Good luck.
The guy speculates that the primary endpoint was not met. But he doesn't explain how he can know this. Did patients not respond and die sooner than expected? Nope. In fact, the event rate has been far lower than expected, so many patients must have responded! If patients are living far longer than expected, it seems reasonable to expect that they responded to the treatment, don't you think?
Again, I have no position in this stock, I have been just researching it lately with an interest to buy and was about to pull the trigger until I found the above article. It seems to make complete sense to me, but would love to heare anyone's arguments....
I couldn't post the link but if you google: provectus pharmaceuticals allovectin the article will come up as the first search result...
Again would love to hear everyone's thoughts on here!